These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 12199723)
21. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Leach JP; Girvan J; Paul A; Brodie MJ J Neurol Neurosurg Psychiatry; 1997 Apr; 62(4):372-6. PubMed ID: 9120451 [TBL] [Abstract][Full Text] [Related]
22. Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study. Appleton R; Fichtner K; LaMoreaux L; Alexander J; Maton S; Murray G; Garofalo E Dev Med Child Neurol; 2001 Apr; 43(4):269-73. PubMed ID: 11305405 [TBL] [Abstract][Full Text] [Related]
24. Safety profile of orlistat: results of a prescription-event monitoring study. Acharya NV; Wilton LV; Shakir SA Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401 [TBL] [Abstract][Full Text] [Related]
25. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Anhut H; Ashman P; Feuerstein TJ; Sauermann W; Saunders M; Schmidt B Epilepsia; 1994; 35(4):795-801. PubMed ID: 8082624 [TBL] [Abstract][Full Text] [Related]
27. Gabapentin add-on treatment: how many patients become seizure-free? An open-label multicenter study. Mayer T; Schütte W; Wolf P; Elger CE Acta Neurol Scand; 1999 Jan; 99(1):1-7. PubMed ID: 9925232 [TBL] [Abstract][Full Text] [Related]
28. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group. Epilepsy Res; 1994 May; 18(1):67-73. PubMed ID: 8088258 [TBL] [Abstract][Full Text] [Related]
29. Monotherapy trials with gabapentin for partial epilepsy. Beydoun A Epilepsia; 1999; 40 Suppl 6():S13-6; discussion S73-4. PubMed ID: 10530677 [TBL] [Abstract][Full Text] [Related]
30. [Safety and tolerability of gabapentin]. Viteri C Rev Neurol; 2002 Feb 1-15; 34(3):292-5. PubMed ID: 12022084 [TBL] [Abstract][Full Text] [Related]
32. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Layton D; Clarke A; Wilton LV; Shakir SA Osteoporos Int; 2005 May; 16(5):490-500. PubMed ID: 15309382 [TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of gabapentin. Ramsay RE Neurology; 1994 Jun; 44(6 Suppl 5):S23-30; discussion S31-2. PubMed ID: 8022537 [TBL] [Abstract][Full Text] [Related]
34. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Tallian KB; Nahata MC; Lo W; Tsao CY Epilepsia; 1996 May; 37(5):501-2. PubMed ID: 8617181 [TBL] [Abstract][Full Text] [Related]
35. Determination of gabapentin-lactam in serum of patients under gabapentin therapy. Knörle R; Feuerstein TJ; Schulze-Bonhage A Arzneimittelforschung; 2004; 54(3):139-42. PubMed ID: 15112859 [TBL] [Abstract][Full Text] [Related]
36. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. Biswas PN; Wilton LV; Shakir SW J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541 [TBL] [Abstract][Full Text] [Related]
38. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Wong IC; Chadwick DW; Fenwick PB; Mawer GE; Sander JW Epilepsia; 1999 Oct; 40(10):1439-45. PubMed ID: 10528941 [TBL] [Abstract][Full Text] [Related]
39. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. Twaites BR; Wilton LV; Shakir SA J Psychopharmacol; 2007 Jun; 21(4):392-9. PubMed ID: 17656426 [TBL] [Abstract][Full Text] [Related]